和鉑醫藥-B(02142.HK):西奈山與一名第三方訂立獨家授權協議
格隆匯7月19日丨和鉑醫藥-B(02142.HK)發佈公吿,公司獲西奈山伊坎醫學院(屬西奈山醫療系統的一部分)吿知,其已就擁有SARS-COV-2 (COVID-19)中和特徵的一系列抗體與一名第三方訂立獨家授權協議。該授權亦考慮訂約方可能尋求未來協作開發可供治療應用的人源化單克隆抗體。
根據西奈山與公司於2019年10月11日訂立的學術合作協議,西奈山已透過與公司的附屬公司Harbour BioMed US, Inc.的協作,開發一系列COVID-19病毒中和抗體。根據合作協議,公司有權收取西奈山自該授權獲得的收益的25%,其屬合作協議中擬進行的研究計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.